Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Gets Until April 2020 To Decide On Biosimilar Botox Collaboration With Revance

Executive Summary

Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.

You may also be interested in...



Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Mylan Still Mulling Revance's Botox Biosimilar

Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.

Revance Awaits Mylan Decision On Botox Biosimilar

Revance Therapeutics is evaluating its options for developing a biosimilar version of Allergan’s globally renowned Botox cosmetic brand, as it waits for Mylan to decide whether to press on with the opportunity or opt out, per terms agreed last August.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel